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The type II phosphatidylinositol 4-kinases (PI4KIIs) produce the lipid 
phosphatidylinositol 4-phosphate (PtdIns4P) and participate in a confusing variety 
of membrane trafficking and signalling roles. This review argues that both historical 
and contemporary evidence supports the function of the PI4KIIs in numerous 
trafficking pathways, and that the key to understanding the enzymatic regulation is 
through membrane interaction and the intrinsic membrane environment. 
By summarising new research and examining the trafficking roles of the PI4KIIs in 
the context of recently solved molecular structures, I highlight how mechanisms of 
PI4KII function and regulation are providing insights into the development of 
cancer and in neurological disease. I present an integrated view connecting the 
cell biology, molecular regulation and roles in whole animal systems of these 
increasingly important proteins. 
  



































































The phosphatidylinositol 4-kinases (PI4Ks) occupy a central position in 
phosphatidylinositol (PtdIns) metabolism because they catalyse the first step in the 
biosynthesis of four of the seven phosphoinositide (PI) lipids,[1] all of which are 
intimately involved in membrane trafficking.[2, 3] Their primary enzymatic product, 
phosphatidylinositol 4-phosphate (PtdIns4P), is a signalling precursor and an 
important regulator of membrane traffic[3] that can be produced by either of the four 
PI4K activities. The extensively studied type III PI4Ks (PI4KIIIα and PI4KIIIβ) were 
the first PI4K enzymes to be identified at the molecular level and these isoforms 
produce PtdIns4P at the plasma membrane (PM) and Golgi, respectively (reviewed 
in depth elsewhere [4, 5]). The type II PI4KIIs (PI4KIIα and PI4KIIβ) were identified 
more recently[6, 7] and we are only now beginning to understand in detail how they 
influence membrane identity and trafficking. 
PI4KII was first described decades ago as a membrane-bound enzyme 
activated by non-ionic detergents and inhibited by adenosine.[6, 7] For many years, 
interest in PI4K activities was driven by their requirement in PtdIns(4,5)P2-
dependent signalling at the plasma membrane. However, recent years have seen 
profound advances in our understanding of PI4KII in membrane trafficking that 
have largely eclipsed the role of PI4KII in signalling. The functions of PtdIns4P 
have also expanded into a much broader subcellular distribution than previously 
envisaged. Discrete pools of PtdIns4P outside of the Golgi are now recognised on 
early (EE) and sorting endosomes (SEs), late endosomes (LEs), at the plasma 
membrane (PM)[8-10] and even on different subdomains of the trans-Golgi network 
(TGN)-endosomal system[11] (Figure 2). The PI4KIIα and PI4KIIβ enzymes have 
also been detected at the PM and in endosomal compartments containing 
PtdIns4P. Subcellular distribution of both PI4KII isoforms and the PIs they produce 
is therefore broad and overlapping, leading to questions of whether the enzymes 
have redundant functions. 
We now have much information relating to the trafficking events controlled 
by these enzymes and the PtdIns4P they synthesise. The recently solved 
structures of the PI4KII isoforms place their hitherto mysterious properties into a 
molecular framework, thereby allowing us to rationalise their functions and explain 
the unique biochemistry of these two key PI kinases. This review discusses the 

































































structure and function of the PI4KIIs, the differences and similarities in their 
regulation and their involvement in physiological processes and disease. 
 
2. The PI4KIIs are an ancient kinase family 
 
The PI4KII family eluded molecular identification for many years because their 
gene sequences differed from those of known PI kinases.[12, 13] Discovery of the 
alpha isoform (PI4KIIα) revealed an unexpected second isoform that we termed 
PI4KIIβ.[13] The PI4KIIs are distinct from the PI4KIII family whose members are 
clearly homologous to the archetypal protein kinase PKA and the PI3Ks, thereby 
placing the PI4KII structures unequivocally within the PI3K/protein kinase 
superfamily.[5] 
Three-dimensional structures of recombinant human PI4KIIα have been 
reported recently[14, 15] and the data subjected to extensive molecular modelling to 
predict biochemical behaviour of the proteins. These studies illustrate how the 
enzymes differ from the phosphoinositide 3-kinase (PI3K) superfamily and how the 
PI4KIIs interact with membranes. The structures also offer explanations for several 
unique biochemical properties of the PI4KIIs such as sensitivity to detergent, 
cholesterol and adenosine that were first described during the characterisation of 
purified PI4KII activity. The models also provide valuable insights into the 
regulation of PI4KII activity. 
PI4KIIα has a flattened interface that contacts membranes, similar to 
features reported for the PI3Ks and phosphatidylinositol 4-phosphate 5-kinases 
(PIP5Ks),[16] suggesting that these evolutionarily distant proteins have retained a 
structural characteristic determining membrane interaction. Overall the catalytic 
domain of PI4KIIα is similar to PI3Ks in that it is composed of N- and C-terminal 
lobes (Figure 1A) but with additional insertions not found in PI3Ks. A search for 
related structures showed that the closest relatives of PI4KIIα are protein kinases 
such as the Helicobacter pylori pro-inflammatory kinase CTKA, thus indicating an 
ancient evolutionary relationship with the protein Ser/Thr kinases. 
PI4KIIα has a nucleotide-binding pocket distinct from those found in PI3Ks, 
which accounts for its insensitivity to PI3K inhibitors such as wortmannin. Another 
feature significantly different from the PI3Ks is a glycine-rich loop (G-loop)[14] that is 
likely to determine nucleotide-binding specificity and is potentially responsible for 

































































the sensitivity of PI4KIIα to adenosine. Co-crystallisation of PI4KIIα in the presence 
of ADP indicates that the ATP binding pocket is positioned so that the terminal γ-
phosphate is oriented in direct apposition to the membrane, where its PI substrate 
resides.[15] 
Numerous parts of the PI4KIIα molecule interact with membranes but 
multiple palmitoylation performs a special role by bringing a nearby amphipathic 
helix and the catalytic core close to the membrane (Figure 1B). This causes the 
nucleotide-binding G-loop, a putative kinase activation loop, to interact with 
membranes along with elements that form the PI binding pocket.[14] Together, 
these elements stabilise critical regions of the active site leading to a more robust 
kinase activity. This tight interaction with the membrane and the effect of 
membrane association on activity, may explain why PI4KIIα is regulated mainly by 
membrane composition and the availability of PtdIns substrate.[17] A second 
hydrophobic pocket has been identified in the C-terminal lobe of PI4KIIα[15] and, 
although the physiological ligand that binds this is unknown, candidates include 
cholesterol, an important membrane organiser and PI4KIIα regulator. 
The N-termini of the PI4KIIs lack primary sequence homology, but contain 
protein binding sites that determine isoform-specific functions (Figure 1A). 
Historically, the two PI4KII activities could not be distinguished in cell and tissue 
extracts and, unsurprisingly, the structure of the conserved core of PI4KIIβ is very 
similar to that of PI4KIIα.[18] Recently an isoform-selective small molecule inhibitor, 
PI-273, has been developed that is approximately 30 times more potent against 
PI4KIIα than PI4KIIβ.[19] This compound is capable of differentiating the two 
isoforms and is likely to become an important experimental tool. 
 
2.1 PI4KII activity is tuned by membrane environment 
Evidence that PI4KIIα activity is regulated comes from the finding that membranes 
containing low and high activity pools of the enzyme can be separated by 
subcellular fractionation.[20] It is clear from the three-dimensional structures that 
membrane interaction determines PI4KII activity, and that this is achieved through 
stable multiple S-palmitoylation.[21] This modification tightly anchors PI4KIIα in 
membranes, such that only detergent treatment can release the protein.[12] Close 
membrane interaction renders PI4KIIα activity exquisitely sensitive to its 
membrane environment,[22] being activated by cholesterol[17] and 

































































phosphatidylcholine, but inhibited by acidic lipids such as phosphatidic acid.[23] The 
nature of this interaction is essential to understand how PI4KIIα activity responds 
to a changing environment, in particular the supply of PI substrate. Thus the 
molecular structures support numerous observations that PI4KIIα is regulated 
largely by intrinsic membrane factors.  
PI4KIIα activity is responsible for a large proportion of total PI4K activity in 
cell extracts but, in contrast, PI4KIIβ activity is difficult to measure.[24] Unlike 
PI4KIIα, a substantial proportion of PI4KIIβ is extractable without the need for 
detergent[25] indicating that it is only partially membrane associated, and it is likely 
that this difference is key to the regulation of PI4KIIβ activity. Unlike PI4KIIα, the 
PI4KIIβ isoform is dynamically palmitoylated on cysteine residues within the 
conserved 170CCPCC174 motif (Figure 1A). Membrane recruitment of PI4KIIβ is 
regulated and occurs in response to growth factors and on expression of 
constitutively active Rac1.[26] 
PI4KIIβ binds the molecular chaperone HSP90 through a site in the C-
terminal lobe, a region that is occluded in the tightly membrane bound PI4KIIα. 
This interaction stabilises cytosolic PI4KIIβ and prevents palmitoylation, and 
therefore membrane recruitment. lnhibition of the interaction releases PI4KIIβ 
leading to degradation in the proteosome (Figure 3B). However, acute inhibition of 
the interaction leads to rapid palmitoylation and translocation to TGN and plasma 
membranes. This interaction is likely to be regulated by external stimuli because 
treatment with EGF or PDGF is sufficient to disrupt the HSP90-PI4KIIβ complex.[27] 
Thus, it appears that both protein turnover and membrane translocation, and 
therefore substrate access, are under tight control. This indicates the existence of 
elaborate mechanisms controlling PI4KIIβ activity, and suggests that this isoform is 
subject to stringent regulation in a manner quite distinct from PI4KIIα. 
 
2.3 The lipid products of PI4KIIs can be studied at the subcellular level 
 
Spatially distinct pools of PIs can be imaged at subcellular resolution by using 
recombinant probes that are now widely used in microscopy. [28] The use of these 
has confirmed the existence of PtdIns4P in the PM and, surprisingly, in multiple 
endosomal compartments ([8, 10, 29], Figure 2). 

































































PtdIns4P levels on intracellular membranes are determined by the 
localisation and activity of the resident PI4Ks, but a central problem in the study of 
PI4KII function is that the PtdIns4P produced is indistinguishable from the 
enzymatic products of other PI4K isoforms. Two other issues further complicate 
PtdIns4P experiments: remarkably, some PtdIns4P pools can supply lipid to 
adjacent membranes through non-vesicular traffic,[30] making it technically difficult 
to assign a membrane compartment to an individual isoform; also, dynamic 
changes in PtdIns4P levels may not be detectable, for example, when PtdIns4P is 
rapidly converted to another PI. These cautions notwithstanding, cellular imaging 
and the manipulation of PIs has proved decisive in understanding PI4KII function. 
The biosynthesis of PtdIns4P by different PI4K isoforms can occur in 
metabolically separate pools.[10, 11] Connecting each of these pools to a particular 
PI4KII activity in the absence of effective inhibitors has been challenging; however, 
the Balla laboratory has adopted and developed techniques to acutely manipulate 
PIs in different organelles by the inducible targeting of PI phosphatases.[31] Thanks 
to this approach, which has since been used by several investigators, we know that 
PtdIns4P is produced in the PM by PI4KIIIα[8] (as was predicted by many earlier 
studies[10]), that PtdIns4P can regulate a PM calcium channel[32], that PtdIns4P is 
present in LE and lysosomal membranes[8] and that PtdIns4P metabolism occurs 
during phagosomal maturation.[33] 
 
3. PI4KIIs have multiple roles in membrane trafficking 
 
Early studies indicated that the PI4KIIs localise to, and traffic between, the Golgi 
complex and endosomes[20, 24, 34]. It is now clear that most trafficking pathways 
involving PI4KIIs can be traced back to the TGN; however, to understand the 
multitude of PI4KII pathways, it is important to recognise the complexity of 
communication between the TGN and endosomal compartments, which are highly 
heterogeneous and ultimately traffic cargo to the lysosome or PM.[35] The TGN is 
itself a highly dynamic, PtdIns4P-rich compartment at the trans face of the Golgi 
apparatus that functions as an exit point where cargo is sorted into biosynthetic 
and endosomal pathways. The TGN also receives backward (retrograde) traffic 
from endosomal compartments.[36] The TGN therefore, plays critical functions as a 
sorting hub that coordinates many aspects of intracellular traffic, including 
secretion and the biogenesis of lysosomes and related organelles. PI4KIIα, PI4KIIβ 

































































and the PtdIns4P the enzymes produce, all function at the TGN and associated 
membranes, and the following sections describe how the PI4KIIs function in these 
processes. 
 
3.1 How the PI4KIIs control traffic. 
 
PtdIns4P is a factor in the recruitment of several clathrin adaptors at the TGN and 
therefore in determining the sorting of proteins into distinct pathways. For example, 
EpsinR is a PtdIns4P-binding protein that mediates TGN-to-endosome cargo 
sorting,[37] as are the Golgi-localised γ-ear-containing Arf binding proteins 
(GGAs),[38] which require PtdIns4P synthesised by PI4KIIα for correct 
localisation.[39] PI4KIIα is a significant PtdIns4P biosynthetic activity at the TGN 
and it was originally reported that depletion of the enzyme delocalises the clathrin 
adaptor and PtdIns4P effector AP-1,[40] which principally directs TGN-to-endosomal 
traffic. However, subsequent studies have failed to demonstrate colocalisation or 
direct interaction between PI4KIIα and AP-1.[9, 41, 42] Instead PI4KIIα forms a direct 
complex with another adaptor, AP-3, via its dileucine interaction motif 
56ERQPLL61[42] (Figure 1A). AP-3 controls traffic from EE/SE into the 
endolysosomal pathway.[43] The finding that PI4KIIα is a component of AP-3 
containing vesicles, along with many AP-3 cargoes,[44] further supports the 
involvement of PI4KIIα in EE/SE-to-LE traffic (Figure 3A). 
PI4KIIβ is also found in the TGN where it colocalises with AP-1, and to a 
lesser degree with EE and LE markers, indicating that PI4KIIβ is distributed 
between the TGN and endosomal systems. PI4KIIβ contains the N-terminal 
dileucine sequence 25EREPLL30 that specifically binds AP-1, rather than AP-3.[45] 
This AP-1 complex is required to localise PI4KIIβ to the TGN and PI4KIIβ 
knockdown causes mislocalisation of AP-1, indicating that the proteins are 
functionally interdependent. Importantly, by virtue of their adaptor recognition 
motifs, both PI4KII isoforms are effectively cargoes that promote the recruitment of 
their cognate adaptors. In the case of PI4KIIβ/AP-1, this depends on the 
biosynthetic activity of PI4KIIβ; whereas, with PI4KIIα/AP-3, despite having a 
requirement for both kinase activity and an intact dileucine motif, evidence 
supporting a direct role for PtdIns4P in AP-3 recruitment has been elusive. 
However, the PI4KII isoforms synthesise spatially separate pools of PtdIns4P in 

































































the TGN-endosomal system[11] (Figure 2) and a pool of PtdIns4P is required for 
AP-3 cargo trafficking,[46, 47] arguing that both PI4K-adaptor systems are dependent 
on PtdIns4P. In summary, it is clear that PI4KII isoforms operate in different post-
TGN trafficking pathways by utilising distinct PI4KII-dependent clathrin adaptor 
systems, and that the PI4KIIα/AP-3 and PI4KIIβ/AP-1 complexes exhibit a similar 
reciprocal relationship between location and function. 
 
3.2 Late endosomal traffic: degradation or recycling? 
 
The epidermal growth factor receptor (EGFR) is a potent tyrosine kinase 
and significant human oncogene that, when activated, is rapidly downregulated by 
traffic to late endosomes (LEs). PI4KIIα is necessary for efficient EGFR trafficking 
and degradation,[34] and whilst PI4KIIα may play a role in trafficking the receptor 
into the LE pathway, the traffic of hydrolytic enzymes to the lysosome may also 
contribute indirectly to impaired degradation in siRNA-treated cells.[47] Furthermore, 
EGFR degradation is likely to be influenced by interaction of PI4KIIα with the 
ubitquitin proteosome system. PI4KIIα directly binds to the E3 ubiquitin ligase Itch 
at the TGN-endosome boundary, an interaction that increases Itch ubiquitin ligase 
activity whilst decreasing PI4KIIα activity. This interaction has important functional 
consequences for canonical Wnt signalling because the formation of the complex 
has the effect of facilitating the sorting of frizzled receptors for degradation, thereby 
determining the output of this major developmental signalling pathway.[41] 
After they exit the TGN, newly synthesised soluble hydrolases rely on 
mannose-6-phosphate receptors (M6PR) for delivery to lysosomes.[48] Depletion of 
either PI4KIIα or PI4KIIβ affects traffic of the cation-independent M6PR, which is 
an AP-1 cargo sorted to the LE through an AP-3 pathway, and it is likely that 
PtdIns4P generated by the PI4KII isoforms is responsible for this.[40, 45] PI4KIIα is 
required for co-trafficking of the lysosomal hydrolase β-glucocerebrosidase (GBA) 
and its receptor, the AP-3 cargo LIMP-2. GBA is essential for the metabolism of 
lysosomal glucosylceramide and mutations in GBA that affect binding to LIMP-2 
lead to missorting and lysosomal accumulation of glucosylceramide. Interestingly, 
although PI4KIIα binds AP-3, and is clearly active in SE membranes, kinase dead 
PI4KIIα is able to partially rescue AP-3 trafficking defects.[42, 47] It is currently 

































































unclear why this phenomenon occurs but it is possible that an alternative activity is 
responsible for generating PtdIns4P at this locus. 
Phagocytic cells use endosomal trafficking to deliver internalised pathogens 
and cell debris to the lysosome. As with endolysosomal traffic, phagosomes 
undergo maturation through early and late compartments, finally fusing with 
lysosomes. Two phases of PtdIns4P synthesis occur on maturing phagosomes: 
initially a transient phase, probably the result of PI4KIIIα activity, followed by a 
sustained phase that precedes lysosomal fusion that corresponds to the late stage 
of phagocytosis. Mature phagocytic membranes contain PI4KIIα, which 
synthesises PtdIns4P during this phase of maturation.[33, 49] This PtdIns4P pool 
presumably mediates traffic and fusion with lysosomes, probably by recruitment of 
the Rab7 effector RILP. An analogous heterotypic fusion process has been 
described involving the Atg8 family member γ-aminobutyric acid receptor-
associated protein (GABARAP) that binds to and colocalises with PI4KIIα on 
autophagic structures, along with PtdIns4P (Figure 2).[46, 50] siRNA of PI4KIIα or 
overexpression of the inactive kinase leads to the accumulation of enlarged 
autophagosomes, whose appearance can be phenocopied by GABARAP 
depletion. This phenotype can be rescued with exogenous PtdIns4P;[50] therefore, 
the formation of large autophagosomes may be due to preventing the local 
generation of PtdIns4P and the impairment of autophagosome-lysosome fusion. 
The parallels between the processes of phagocytosis and autophagy are clear and 
it is likely that the role of PI4KIIα in heterotypic fusion is conserved. 
 
3.3 PI4KIIs determine the fate of cargoes through TGN sorting and 
endosomal exit. 
 
PI4KIIα exists in varying amounts in the TGN, EE, LE, recycling 
compartments and at the PM (Figure 3A). Mechanistic information on the trafficking 
steps that determine this broad subcellular distribution is, however, scarce. We 
know that siRNA of PI4KIIα results in the mislocalisation of recycling[24] and late 
endosomal cargoes,[34, 44] and impaired sorting of the epidermal growth factor 
receptor (EGFR) and transferrin to degradative and recycling fates, respectively.[9] 
It appears that, rather than dynamic recruitment of the enzyme, the constitutively 
membrane-bound PI4KIIα is sorted, cargo-like, into different pathways through 

































































interaction with SNAREs. PI4KIIα binds to the R-snare VAMP3 on SEs where it 
facilitates retrograde delivery back to the TGN. Furthermore, the close homolog 
VAMP7 was identified as a component of AP-3 and PI4KIIα-containing vesicles,[42] 
where it mediates fusion with the LE. Thus converging evidence supports a role for 
SNAREs and PI4KIIα in sorting into retrograde recycling and LE pathways, 
probably determining the balance of traffic between these diverging routes (Figure 
3A). 
The association of PI4KII with membranes derived from secretory tissues is 
well documented and extracts of these have proved to be rich sources of activity.[7, 
12] Aside from the work describing PI4KII in the control of post-TGN and endosomal 
trafficking, there is also a substantial body of work supporting a role for PI4KIIα in 
traffic towards the PM (Table 2; Figure 3A). An explanation for this is provided by 
the fact that endosomal compartments can serve as intermediates in trafficking to 
the plasma membrane, particularly in specialised secretory cells.[51] Such a 
pathway has been described originating at EE/SEs (Figure 3A) that involves the 
PtdIns3P-phosphatase myotubularin 1 (MTM1).[52] Hydrolysis of endosomal 
PtdIns3P is required during the exocytotic step returning the unloaded TfR to the 
plasma membrane. Failure to hydrolyse PtdIns3P results in impaired exit from 
endosomes, and consequently, the accumulation of exocytic cargoes. Normally, 
MTM1 is recruited to PtdIns3P-containing EE/SEs that also harbour PI4KIIα[24, 34, 
53] and when PtdIns3P is hydrolysed, the PtdIns produced becomes a substrate for 
resident PI4KIIα In the context of a membrane in which the supply of PtdIns 
may be limited, and where the local environment is optimal for kinase activity, then 
the result would be increased local PtdIns4P synthesis, effectively converting 
PtdIns3P on EE/SEs into PtdIns4P. This is a significant switch in membrane 
identity because PtdIns3P-positive endosomes are unable to fuse with the PM; 
however, vesicles containing PtdIns4P, that arise from the closely connected RE, 
can (Figure 3A).[52] Generation of PtdIns4P also leads to recruitment of the exocyst 
complex, which interacts with PI4KIIα. Exocyst mediates the docking and 
membrane insertion of exocytic and recycling cargoes such as TfR and integrin β1; 
therefore, MTM1 and PI4KIIα forms a conversion module controlling endosomal 
exocytosis by switching PI metabolism from PtdIns3P to PtdIns4P. It also shows 
that PI4KIIα is a more versatile enzyme that functions, not only in trafficking to the 
LE and terminal processes such as lysosomal fusion but also in anterograde traffic. 


































































3.4 PI4KII-mediated traffic is linked to the actin cytoskeleton 
 
Numerous actin-binding proteins interact both with PIs and elements of endocytic 
machinery, thereby linking PI metabolism with actin dynamics in membrane 
trafficking processes. For example, actin polymerisation is required to propel newly 
endocytosed cargoes though the cytoplasm on comet-like structures,[54] and 
requirements for actin polymerisation have been identified in LE to lysosomal traffic 
and in recycling. The Wiskott-Aldrich syndrome (WAS) family of actin branching 
regulators are targets of PtdIns(4,5)P2 that are frequently implicated in endosomal 
trafficking pathways.[55] A clue that PI4KII enzymes may have a conserved role in 
actin-dependent endocytic traffic comes from the sole PI4KII homolog of the yeast 
S. cerevisiae, Lsb6, which is a binding protein of the yeast Wiskott-Aldrich 
syndrome protein (WASp) homolog Las17.[56] 
During phagocytosis and Listeria monocytogenes infection, movement 
through the cytoplasm is accompanied by the dynamic formation of actin-rich 
comets. These require the coordinated activities of actin nucleating machinery 
ARP2/3, Ena-VASP and WASp. Both PI4KII isoforms are recruited to internalised 
beads coated with the bacterial cell surface protein InlB and these 
pseudophagosomes become decorated with PtdIns4P.[57] 
PI4KIIα exists in complex with a large number of actin regulatory proteins 
including RhoGEF1 and several subunits of the actin nucleation promoting WASH 
complex,[41, 53] which, together with Arp2/3, regulates endosome morphology and 
trafficking.[58] PI4KIIα also colocalises with fluorescent actin on EEs that contain 
branched actin. The close association of PI4KIIα with actin regulatory machinery 
and the necessity for PtdIns4P synthesis on endosomes together suggests that 
PI4KIIα participates in the synthesis of an EE pool of PtdIns(4,5)P2. In support of 
this, we recently demonstrated that PtdIns4P and PtdIns(4,5)P2 exist in separate 
endosomal microdomains and that PI4KIIα is required for correct early endosomal 
sorting of the EGFR and Tf through the synthesis of PtdIns4P.[9] 
PtdIns(4,5)P2 levels in the EE are controlled by the PtdIns(4,5)P2 5-
phosphatase OCRL, depletion of which leads to an N-WASp-dependent increase 
in endosomal F-actin and consequently the mistrafficking of TfR, EGFR and 
M6PR.[59] Ectopic accumulation of PtdIns4P and PtdIns(4,5)P2 is also observed 
when PtdIns4P hydrolysis by the PtdIns4P phosphatase Sac1 is inhibited at 

































































endosome-ER contacts, resulting in aberrant trafficking of retrograde cargoes [60]. 
Interestingly, the activity of OCRL is also required on SEs to maintain correct traffic 
of multiple endosomal cargoes.[59] Together this evidence demonstrates the 
importance of regulating the levels of endosomal PtdIns4P and PtdIns(4,5)P2 and, 
as the principal sources of early endosomal PtdIns4P, the PI4KIIs are likely to 
assume greater importance at this site in the future. 
 
4. PI4KIIs modulate Wnt signalling 
 
Wnt ligands control major developmental signalling cascades that are frequently 
dysregulated in human cancers.[61] Both PI4KIIα and type Iβ phosphatidylinositol 4-
phosphate 5-kinase (PIP5KIβ) bind to, and are activated by, the Wnt scaffolding 
protein Dvl in a multiprotein complex synthesising PtdIns(4,5)P2.
[62] Knockdown of 
PI4KIIα causes axis duplication in Xenopus,[63] a developmental defect linked to 
aberrant Wnt signalling. Another study showed that knockdown of PI4KIIα impaired 
the internalisation, endosomal traffic and degradation of the Wnt receptor frizzled 
(Fz) 4.[41] It is therefore likely that PI4KIIα is involved in at least two regulatory 
steps in canonical Wnt signalling: the formation of an activated signalling complex 
with Dvl promoting PM PtdIns(4,5)P2 synthesis at the PM and in a sorting complex 
that facilitates traffic to degradative compartments.  
Knockdown of Zebrafish PI4KIIβ affects Wnt target gene expression and 
causes developmental defects. In cell lines, the kinase exists in a complex with Dvl 
and axin1, both components of the canonical Wnt signalling cascade. Depletion of 
PI4KIIβ leads to accumulation of endocytosed Fz in LEs, probably in transit for 
degradation. This accumulation can be rescued by ectopic expression of PI4KIIβ 
but not with a mutant incapable of AP-1 binding, indicating that AP-1 dependent 
trafficking underlies the phenomenon. Consistent with this, the AP-1 complex is 
known to be important for traffic to basolateral domains of epithelial cells[64] in 
developing embryos and interference with AP-1 perturbs the Wnt planar cell 
polarity (PCP) pathway[65] important for organisation of embryonic tissues. 
 
 
5. PI4KII are associated with cancer 
 

































































Both elevated and reduced levels of PI4KIIα expression are associated with 
cancers. For example, elevation has been detected in a diverse panel of human 
tumours and increasing PI4KIIα expression was observed during the development 
of tumours in a mouse xenograft model.[66] Meanwhile, ectopic overexpression of 
PI4KIIα but not a kinase dead mutant was sufficient to induce expression of HIF-
1α, an important factor allowing cells to survive the hypoxic tumour environment. 
The same group subsequently showed that PI4KIIα siRNA leads to degradation of 
Her2 and EGFR, and overexpression to Her2 activation.[67] Whilst the data 
supporting the hypothesis that PI4KIIα positively regulates EGFR levels and 
signalling is comprehensive and compelling, it is at odds with the established LE 
roles of PI4KIIα and in regulating the degradation of the EGFR[34] and the fact that 
loss rather than gain of the PI4K2A gene is associated with an aggressive brain 
cancer.[68] However, PI4KIIα depletion studies have revealed complex effects on 
both the supply of PtdIns4P for signalling and membrane trafficking.[69] Thus it is 
likely that these discrepancies may reflect the inherent heterogeneity of tumours; 
nevertheless, it is clear that the dual targeting of EGFR family kinases and PI4KIIα 
holds some promise as a personalised chemotherapeutic approach in certain 
cancers.[67] 
PI4KIIβ has been implicated in regulation of cell migration and metastasis of 
hepatocellular carcinoma through interaction with the tetraspanin CD81,[70] a 
molecule that has been shown previously to co-purify with PI4KII activity.[71] siRNA 
of PI4KIIβ leads to the formation of invasive structures, increased extracellular 
matrix degradation by the matrix type I metalloproteinase (MT1-MMP) and 
increased motility through collagen gels, thus indicating that PI4K2B has properties 
consistent with a suppressor of metastasis. In the same work, oncogenomic 
studies identified PI4KIIβ loss as a risk factor in cancer.[11] 
 
5.1 PI4KIIα is linked to neurological disease 
 
Loss of PI4KIIα in mice leads to impaired neurological function resembling human 
spastic paraplegia, eventually resulting in premature death.[72] It is difficult to 
pinpoint a single trafficking step that may account for these defects given that 
PI4KIIα functions in LE, retrograde traffic and exocytosis but, in addition to axonal 
pathology, the mice show accumulation of lipofuscin-like deposits and membrane 

































































inclusions. This is consistent with deficient LE traffic or EE/SE exit to the Golgi[46, 47] 
(Figure 4) and such trafficking defects would explain the axonal degeneration and 
neuron loss in these mice. 
Aberrant endolysosomal traffic is frequently associated with late onset 
neurodegenerative diseases.[73] As mentioned above, PI4KIIα is responsible for the 
traffic of GBA from the TGN to endosomes where the complex is routed to 
lysosomes. Failure of this hydrolase to reach lysosomes results in failure to 
catabolise glucosylceramide and the accumulation causing Gaucher disease, the 
most common human lysosomal storage disease. 
The ability PI4KIIα to bind AP-3 and recruit the clathrin adaptor to 
membranes has important implications for traffic to lysosomes and lysosomal-
related organelles. Hermansky-Pudlak syndrome is a rare autosomal recessive 
disease characterised by albinism and bleeding disorders. Like hereditary spastic 
paraplegia, Hermansky-Pudlak syndrome is genetically heterogeneous and can 
result from mutation in a number of loci encoding proteins involved in 
endolysosomal traffic. Clinical presentation and histopathology shows little in 
common with hereditary spastic paraplegia, but like the PI4KIIα mouse knockout, 
lipofuscin deposition can be observed in some tissues. The adaptor complex AP-3 
is just one gene affected in Hermansky-Pudlak syndrome, and PI4KIIα associates 
with multiprotein complexes known to be involved in Hermansky-Pudlak 
syndrome.[74] 
Loss of function mutations of the MTM1 gene encoding a PI3-phosphatase 
leads to X-linked centronuclear myopathy (XLCNM), a severe congenital 
neuromuscular disease. As discussed previously, hydrolysis of endosomal 
PtdIns3P and salvage of the PtdIns formed by PI4KIIα appears to be a prerequisite 
for exocytic trafficking to the plasma membrane (Figure 4). Specific inhibitors for 
the PI 3-kinase hVPS34 have been developed and were shown to restore exocytic 
traffic to the PM,[52] suggesting that they could form the basis for treatment of 
XLCNM. 
Cholesterol, a membrane constituent and activator of PI4KIIα, has long 
been implicated in the pathogenesis of Alzheimer’s disease.[75] Steroid-like natural 
ginsenosides can reduce the accumulation of the amyloidogenic Aβ   in 
cultured neurons and the brains of an Alzheimer’s mouse model, whilst enhancing 
the activity of PI4KIIα and increasing the levels of PtdIns4P and PtdIns(4,5)P2 in 

































































cultured cells.[76] Cholesterol and sterol analogs are able to activate PI4KIIα,[17] and 
although PI4KIIα has not been directly implicated in the pathology of Alzheimer’s 
disease in recent gene studies, a plausible therapeutic strategy might be the up-
regulation PI4KIIα activity, or the inhibition of PI 4-phosphatases, to protect against 
the development of AD. However, testing this hypothesis would require 
exceptionally demanding longitudinal studies. 
  
6. Conclusions: Integrating PI4KII functions 
The discovery of PtdIns4P on early and late endosomes, as well as the TGN, 
challenges the prevailing view that PtdIns3P is an exclusive determinant of 
endosomal membrane identity. It is now clear that PtdIns4P synthesis by PI4KII 
isoforms at these membranes performs decisive roles in cargo selection, sorting 
and in directing traffic. In early endosomes, PtdIns3P can be converted to PtdIns4P 
via dephosphorylation to the common PtdIns precursor to accomplish endosomal 
exit and traffic toward the plasma membrane. A similar relationship between 
PtdIns3P and PtdIns4P has been noted during phagosomal maturation, suggesting 
that comparable conversion mechanisms exist in other trafficking pathways. Also, 
local PtdIns4P synthesis by PI4KIIs can recruit different clathrin adaptors thereby 
controlling the traffic of different cargoes into distinct pathways and adding to the 
complexity of PI4KII trafficking. 
Close membrane interaction as a r sult of palmitoylation is the principal 
determinant of PI4KII activity at membrane interfaces. Unlike all known PI kinases, 
which are invariably recruited to membranes containing their substrates, PI4KIIα is 
constitutively membrane associated. The emerging model then is one in which 
membrane-bound PI4KIIα is highly sensitive to its membrane environment, 
responding to activation with the local synthesis of PtdIns4P. PI4KIIα activity can 
be further modulated in situ through the binding of proteins such as Itch that can 
regulate activity. Therefore, PI4KIIα appears to be a sensor capable of reacting to 
changes in membrane environment, such as cholesterol content and the local 
availability of PtdIns, with increased synthesis of PtdIns4P. In this way, PI4KIIα 
activity recruits PtdIns4P effector proteins, alters membrane identity and redirects 
traffic from the EE/SE in specific directions such as toward the LE, Golgi or PM. 
The implication here is that membranes containing active PI4KIIα could respond in 
a similar way to many other metabolic activities generating PtdIns. 

































































 Insight into the biology of PI4KIIβ has lagged behind but it is clear that this 
isoform, in contrast to PI4KIIα, can be regulated by extrinsic factors. Extracellular 
signals trigger membrane recruitment of the enzyme and therefore control its 
activity. The plasma membrane location of PI4KIIβ is intriguing because it implies a 
function for PtdIns4P synthesis at the PM, a role currently reserved for PI4KIIIα. 
Also, it is not clear how PI4KIIβ is specifically targeted to the plasma membrane by 
palmitoylation alone, and it is possible that additional factors are required. It is 
likely that PI4KIIβ functions in developmental Wnt signalling at the plasma 
membrane, possibly by maintaining epithelial cell polarity and suppressing a 
migratory program. In support of this, loss of the enzyme is a risk factor in human 
cancers, which is also consistent with the notion that PI4KIIβ is highly regulated 
under physiological conditions. 
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Table 1. Properties of the PI4KII isozymes. TGN, trans-Golgi network; EE, early 
endosome; SE, sorting endosome; LE, late endosome; Pg, phagosome; Lys, 
lysosome; Apg, autophagosome; EV, exocytic vesicle. *A large number of potential 
binding proteins have been identified by affinity purification and mass 
spectrometry, not all of which have been characterised in detail [41, 44, 45, 53, 74]. 
 
Table 2. PI4KIIα in anterograde traffic.  
Summary of evidence showing PI4KIIα in traffic towards the PM. 
 
Figure 1. Structure of the PI4KII enzymes. A. The domain organisation of 
PI4KIIα and PI4KIIβ is highly similar. The divergent N-termini lack homology but 
contain interaction sites for clathrin adaptors. In PI4KIIα, a dileucine sorting motif 
57ERQPLL62 is recognised by AP-3 [41, 42] whilst PI4KIIβ contains a similar 

































































sequence (25EREPLL30) that specifically binds AP-1 [45]. The N-ter of PI4KIIα also 
contains the sequence 15PPDY18 that binds the WW3 domain of the ubiquitin ligase 
Itch, which mediates multi-ubiquitination of PI4KIIα [41]. The conserved catalytic 
core is now known to be composed of amino- (N) and carboxy- (C) terminal lobes. 
Both isoforms contain a conserved palmitoylation motif, 174CCPCC178 in PI4KIIα 
and PI4KIIβ 170CCPCC174. HSP90, which plays a role in the stability and 
membrane recruitment of PI4KIIβ, binds to a region between residues 315-481 in 
the C-lobe [27]. This schematic is based on the human polypeptide sequences 
(NP_060895 and NP_060793.2). B. Model illustrating how the PI binding pocket of 
palmitoylated PI4KIIα interacts with membranes (adapted with permission [14]). 
Boxed area indicates  palmitoylation loop. 
 
Figure 2. The subcellular distribution of PtdIns4P 
PtdIns4P is enriched in the Golgi complex where PI4KIIIβ, PI4KIIα and PI4KIIβ are 
responsible for its synthesis. Imaging methods using recombinant proteins derived 
from PtdIns4P binding domains have revealed pools at the plasma membrane (PM 
[8]), recycling endosome (RE, [52]), early/sorting endosome (EE/SE, [9, 46]), late 
endosome (LE, [8]), lysosome (Lys, [8]), autophagosome (Apg, [50]) and phagosome 
(Pg, [33, 49]. Discrete PI4K activities are responsible for this distribution and it is 
known that PI4KIIIα is a major PtdIns4P biosynthetic activity at the PM (yellow). 
PI4KIIIβ produces a pool in the Golgi apparatus (magenta), whereas PI4KIIα and 
PI4KIIβ produce PtdIns4P on separate domains of the TGN (red and green, 
respectively) [11]. PI4KIIα is also responsible for pools of PtdIns4P on RE [52], SE, 
LE and Apg membranes (blue) that are likely to be dynamically regulated. 
Furthermore, PI4KIIα generates PtdIns4P in late phagosomes. 
TGN, trans-Golgi network; EE, early endosome; SE, sorting endosome; LE, late 
endosome; Pg phagosome; Lys, lysosome; Apg, autophagosome; EV, exocytic 
vesicle; RE, recycling endosome. 
 
Figure 3. The membrane trafficking functions of the type II PI 4-kinases. 
Both PI4KIIα and PI4KIIβ localise to the TGN and endosomes, although it is likely 
that they exist in separate domains within the TGN-endosomal system. A. PI4KIIα 
localises predominantly to the TGN and endolysosomal system but relatively minor 
pools have also been detected at the PM. At the early/sorting endosome (EE/SE), 

































































PI4KIIα recruits AP-3 to membranes participating in traffic to the LE; however, the 
enzyme is also involved in retrograde traffic via a VAMP3-dependent pathway. 
PI4KIIα further functions in degradative pathways by producing PtdIns4P required 
for heterotypic fusion of lysosomal (Lys) and autophagosomal (Apg) membranes 
and an analogous process occurs in phagocytic cells [33, 49]. PI4KIIα mediates 
exocytic traffic from endosomal compartments including the EE/SE via the 
recycling endosome (RE) [52] and in a Rab27a-dependent step from the LE during 
HIV-1 viral assembly in T-cells [77]. 
B. PI4KIIβ is partially cytosolic and is dynamically palmitoylated in response to 
growth factors and expression of constitutively active Rac, which both lead to PM 
recruitment. PI4KIIβ synthesises a pool of PtdIns4P that colocalises with TGN46 
(green; [11]). At the TGN, PI4KIIβ is responsible for recruitment of the clathrin 
adaptor AP-1 [45]. The molecular chaperone HSP90 binds PI4KIIβ preventing 
palmitoylation, thereby maintaining PI4KIIβ in an inactive, cytosolic form whilst 
protecting the protein from proteosomal degradation [27]. 
 
Figure 4. PI4KII trafficking pathways of relevance to human disease. 
Five main pathways are affected by loss of PI4KII function in in vitro or whole 
animal models: TGN-to-endosomal traffic (i) is affected in zebrafish that have lost 
PI4KIIβ, resulting in developmental defects attributed to aberrant Wnt signalling [45]; 
(ii), loss of PI4KIIα impairs endosome-to-TGN traffic facilitated by VAMP3 [46]; 
endolysosomal traffic (iii) is affected by knockdown of PI4KIIα, which impairs 
degradation of lysosomal cargoes such as the EGFR [34], the traffic of lysosomal 
membrane proteins [47] and lysosome-related organelles [78] and likely causes a 
phenotype in mice that is reminiscent of human spastic paraplegia (HSP; [72]. Note 
that this phenotype may reflect a defect in a lysosomal pathway or a retrograde 
step (i.e., ii); (iv) endosome-to-plasma membrane traffic controlled by PI4KIIα is 
affected by in human X-linked centronuclear myopathy (XLCNM) [52]; (v), LE-to-PM. 
PI4KIIα is trafficked from the LE to the PM in HIV infected T-cells [77]. Note that 
both PI4KIIα and PI4KIIβ function in pathways that can culminate in traffic to the 
lysosome; therefore, knockdown of either isoform can give similar late 
endosomal/lysosomal phenotypes, leading some to conclude they have 
overlapping functions. 
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Table 1                  Properties of the PI4KII isozymes 
 PI4KIIα PI4KIIβ 
Subcellular 
distribution 
EE, LE, Pg, PM, Apg TGN, EE, LE, cytosolic 
Principal 
functions 
EE and LE traffic, 
















Recruited in response to 
growth factors (PM) 
Upstream 
regulators 









































































Table 2                  PI4KIIα functions in anterograde traffic 




Glut4 >PM [79] 
Mast cell degranulation [80] 
Regulated secretion [81] 
Secretory granule formation [82] 
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The type II phosphatidylinositol 4-kinases (PI4KIIs) are versatile mediators of membrane trafficking, 
controlling pathways that impact on disease. Recent advanc s suggest that the membrane lipid environment 
regulates enzyme activity and that the complexity of trafficking routes can be explained by the ability of 
these kinases to promote membrane trafficking in different directions.  
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